title: RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted anti-atherosclerotic therapy.
authors.forename: Peter E
authors.initials: PE
authors.lastname: Westerweel
authors.forename: Ton J
authors.initials: TJ
authors.lastname: Rabelink
authors.forename: Maarten B
authors.initials: MB
authors.lastname: Rookmaaker
authors.forename: Hermann-Josef
authors.initials: HJ
authors.lastname: Gröne
authors.forename: Marianne C
authors.initials: MC
authors.lastname: Verhaar
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy* / Q000473:pathology; D065100:CCR5 Receptor Antagonists; D018946:Chemokine CCL5 / Q000494:pharmacology / Q000502:physiology*; D006614:Hindlimb / Q000098:blood supply; D007511:Ischemia / Q000150:complications; D009389:Neovascularization, Pathologic / Q000209:etiology* / Q000517:prevention & control; D051381:Rats
chemical_list: D065100:CCR5 Receptor Antagonists; D018946:Chemokine CCL5; C108335:RANTES, Met-